Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: APost HocAnalysis of the EVOLUTION Study | Zendy

Delia Colombo | Zendy; Carlo Caltagirone | Zendy; Alessandro Padovani | Zendy; Sandro Sorbi | Zendy; Gianfranco Spalletta | Zendy; Lucia Simoni | Zendy; Alessandra Ori | Zendy; Emanuela Zagni | Zendy

Open Access

Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: APost HocAnalysis of the EVOLUTION Study

Author(s) -

Delia Colombo,

Carlo Caltagirone,

Alessandro Padovani,

Sandro Sorbi,

Gianfranco Spalletta,

Lucia Simoni,

Alessandra Ori,

Emanuela Zagni

Publication year - 2018

Publication title -

journal of women s health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.195

H-Index - 98

eISSN - 1931-843X

pISSN - 1540-9996

DOI - 10.1089/jwh.2017.6420

Subject(s) - rivastigmine , apathy , medicine , dementia , post hoc analysis , anxiety , odds ratio , depression (economics) , psychiatry , donepezil , disease , economics , macroeconomics

Alzheimer's disease (AD) is characterized by progressive cognitive decline, often associated with Behavioral and Psychological Symptoms of Dementia (BPSD). Acetylcholinesterase inhibitors (ChEi) may attenuate cognitive decline and mitigate BPSD. The EVOLUTION group found that the switch from oral ChEi to transdermal rivastigmine patch formulation resulted in improvement/stabilization in the frequency of clinically relevant BPSD, but gender-specific subgroup analyses were not reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research